(EXPO) Exponent - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US30214U1025
Stock: Consulting, Engineering, Science, Health
Total Rating 44
Risk 73
Buy Signal -1.04
| Risk 5d forecast | |
|---|---|
| Volatility | 29.4% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.66 |
| Alpha | -28.52 |
| Character TTM | |
|---|---|
| Beta | 0.390 |
| Beta Downside | 0.556 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.55% |
| CAGR/Max DD | -0.25 |
EPS (Earnings per Share)
Revenue
Description: EXPO Exponent March 05, 2026
Exponent, Inc. (EXPO) is a science and engineering consulting firm operating in the United States and internationally. The company is structured into two segments: Engineering and Other Scientific, and Environmental and Health.
EXPO offers a broad range of services including biomechanics, civil engineering, data sciences, electrical engineering, materials science, and vehicle engineering. This extensive service portfolio is typical for diversified consulting firms in the research and consulting services sector.
The company also provides expertise in chemical regulation, food safety, ecological sciences, and health sciences. Their services encompass proactive and reactive product safety, litigation support, and regulatory assistance, serving a diverse client base across industries such as chemical, consumer products, energy, government, life sciences, and manufacturing.
To gain a deeper understanding of EXPOs market position and financial health, further research on ValueRay is recommended.
Headlines to watch out for
- Demand for engineering consulting services drives revenue growth
- Litigation support services impact profitability
- Regulatory changes influence environmental and health segment
- Government spending affects consulting project volume
- Insurance sector demand for expert analysis fluctuates
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 106.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -2.57 > 1.0 |
| NWC/Revenue: 42.88% < 20% (prev 50.80%; Δ -7.91% < -1%) |
| CFO/TA 0.16 > 3% & CFO 131.7m > Net Income 106.0m |
| Net Debt (-139.1m) to EBITDA (152.4m): -0.91 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.6m) vs 12m ago -2.03% < -2% |
| Gross Margin: 40.09% > 18% (prev 0.42%; Δ 3.97k% > 0.5%) |
| Asset Turnover: 73.40% > 50% (prev 71.86%; Δ 1.54% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 7.64
| A: 0.31 (Total Current Assets 427.6m - Total Current Liabilities 178.0m) / Total Assets 808.6m |
| B: 0.83 (Retained Earnings 668.4m / Total Assets 808.6m) |
| C: 0.19 (EBIT TTM 147.3m / Avg Total Assets 792.9m) |
| D: 1.59 (Book Value of Equity 666.2m / Total Liabilities 418.3m) |
| Altman-Z'' Score: 7.64 = AAA |
Beneish M -2.77
| DSRI: 1.08 (Receivables 181.5m/161.4m, Revenue 582.0m/558.5m) |
| GMI: 1.05 (GM 40.09% / 42.15%) |
| AQI: 1.24 (AQ_t 0.29 / AQ_t-1 0.23) |
| SGI: 1.04 (Revenue 582.0m / 558.5m) |
| TATA: -0.03 (NI 106.0m - CFO 131.7m) / TA 808.6m) |
| Beneish M-Score: -2.77 (Cap -4..+1) = A |
What is the price of EXPO shares?
As of March 17, 2026, the stock is trading at USD 66.71 with a total of 503,492 shares traded.
Over the past week, the price has changed by -7.19%, over one month by -2.52%, over three months by -9.72% and over the past year by -18.33%.
Over the past week, the price has changed by -7.19%, over one month by -2.52%, over three months by -9.72% and over the past year by -18.33%.
Is EXPO a buy, sell or hold?
Exponent has received a consensus analysts rating of 3.67.
Therefor, it is recommend to hold EXPO.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.7 | 37.4% |
| Analysts Target Price | 91.7 | 37.4% |
EXPO Fundamental Data Overview March 16, 2026
P/E Trailing = 32.5459
P/E Forward = 30.2115
P/S = 6.2615
P/B = 8.506
P/EG = 2.0325
Revenue TTM = 582.0m USD
EBIT TTM = 147.3m USD
EBITDA TTM = 152.4m USD
Long Term Debt = 82.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.89m USD (from shortTermDebt, last quarter)
Debt = 82.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -139.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.22b USD (3.36b + Debt 82.8m - CCE 221.9m)
Interest Coverage Ratio = unknown (Ebit TTM 147.3m / Interest Expense TTM 0.0)
EV/FCF = 26.33x (Enterprise Value 3.22b / FCF TTM 122.3m)
FCF Yield = 3.80% (FCF TTM 122.3m / Enterprise Value 3.22b)
FCF Margin = 21.02% (FCF TTM 122.3m / Revenue TTM 582.0m)
Net Margin = 18.21% (Net Income TTM 106.0m / Revenue TTM 582.0m)
Gross Margin = 40.09% ((Revenue TTM 582.0m - Cost of Revenue TTM 348.7m) / Revenue TTM)
Gross Margin QoQ = 24.32% (prev 24.94%)
Tobins Q-Ratio = 3.98 (Enterprise Value 3.22b / Total Assets 808.6m)
Interest Expense / Debt = 7.75% (Interest Expense 6.42m / Debt 82.8m)
Taxrate = 27.39% (9.34m / 34.1m)
NOPAT = 106.9m (EBIT 147.3m * (1 - 27.39%))
Current Ratio = 2.40 (Total Current Assets 427.6m / Total Current Liabilities 178.0m)
Debt / Equity = 0.21 (Debt 82.8m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = -0.91 (Net Debt -139.1m / EBITDA 152.4m)
Debt / FCF = -1.14 (Net Debt -139.1m / FCF TTM 122.3m)
Total Stockholder Equity = 415.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.37% (Net Income 106.0m / Total Assets 808.6m)
RoE = 25.51% (Net Income TTM 106.0m / Total Stockholder Equity 415.6m)
RoCE = 29.55% (EBIT 147.3m / Capital Employed (Equity 415.6m + L.T.Debt 82.8m))
RoIC = 25.73% (NOPAT 106.9m / Invested Capital 415.6m)
WACC = 7.31% (E(3.36b)/V(3.44b) * Re(7.35%) + D(82.8m)/V(3.44b) * Rd(7.75%) * (1-Tc(0.27)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.82%
[DCF] Terminal Value 80.37% ; FCFF base≈128.4m ; Y1≈125.3m ; Y5≈126.3m
[DCF] Fair Price = 55.18 (EV 2.58b - Net Debt -139.1m = Equity 2.72b / Shares 49.3m; r=7.31% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: 6.36 | EPS CAGR: -3.50% | SUE: 0.32 | # QB: 0
Revenue Correlation: 70.78 | Revenue CAGR: 3.69% | SUE: 2.53 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.57 | Chg7d=-0.033 | Chg30d=-0.045 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-12-31): EPS=2.36 | Chg7d=-0.098 | Chg30d=-0.087 | Revisions Net=+3 | Growth EPS=+13.8% | Growth Revenue=+10.5%
EPS next Year (2027-12-31): EPS=2.62 | Chg7d=-0.088 | Chg30d=-0.063 | Revisions Net=+2 | Growth EPS=+11.5% | Growth Revenue=+8.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 7.9% - Earnings Yield 3.1%)
[Growth] Growth Spread = +6.3% (Analyst 11.2% - Implied 4.9%)
P/E Forward = 30.2115
P/S = 6.2615
P/B = 8.506
P/EG = 2.0325
Revenue TTM = 582.0m USD
EBIT TTM = 147.3m USD
EBITDA TTM = 152.4m USD
Long Term Debt = 82.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.89m USD (from shortTermDebt, last quarter)
Debt = 82.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -139.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.22b USD (3.36b + Debt 82.8m - CCE 221.9m)
Interest Coverage Ratio = unknown (Ebit TTM 147.3m / Interest Expense TTM 0.0)
EV/FCF = 26.33x (Enterprise Value 3.22b / FCF TTM 122.3m)
FCF Yield = 3.80% (FCF TTM 122.3m / Enterprise Value 3.22b)
FCF Margin = 21.02% (FCF TTM 122.3m / Revenue TTM 582.0m)
Net Margin = 18.21% (Net Income TTM 106.0m / Revenue TTM 582.0m)
Gross Margin = 40.09% ((Revenue TTM 582.0m - Cost of Revenue TTM 348.7m) / Revenue TTM)
Gross Margin QoQ = 24.32% (prev 24.94%)
Tobins Q-Ratio = 3.98 (Enterprise Value 3.22b / Total Assets 808.6m)
Interest Expense / Debt = 7.75% (Interest Expense 6.42m / Debt 82.8m)
Taxrate = 27.39% (9.34m / 34.1m)
NOPAT = 106.9m (EBIT 147.3m * (1 - 27.39%))
Current Ratio = 2.40 (Total Current Assets 427.6m / Total Current Liabilities 178.0m)
Debt / Equity = 0.21 (Debt 82.8m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = -0.91 (Net Debt -139.1m / EBITDA 152.4m)
Debt / FCF = -1.14 (Net Debt -139.1m / FCF TTM 122.3m)
Total Stockholder Equity = 415.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.37% (Net Income 106.0m / Total Assets 808.6m)
RoE = 25.51% (Net Income TTM 106.0m / Total Stockholder Equity 415.6m)
RoCE = 29.55% (EBIT 147.3m / Capital Employed (Equity 415.6m + L.T.Debt 82.8m))
RoIC = 25.73% (NOPAT 106.9m / Invested Capital 415.6m)
WACC = 7.31% (E(3.36b)/V(3.44b) * Re(7.35%) + D(82.8m)/V(3.44b) * Rd(7.75%) * (1-Tc(0.27)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.82%
[DCF] Terminal Value 80.37% ; FCFF base≈128.4m ; Y1≈125.3m ; Y5≈126.3m
[DCF] Fair Price = 55.18 (EV 2.58b - Net Debt -139.1m = Equity 2.72b / Shares 49.3m; r=7.31% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: 6.36 | EPS CAGR: -3.50% | SUE: 0.32 | # QB: 0
Revenue Correlation: 70.78 | Revenue CAGR: 3.69% | SUE: 2.53 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.57 | Chg7d=-0.033 | Chg30d=-0.045 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-12-31): EPS=2.36 | Chg7d=-0.098 | Chg30d=-0.087 | Revisions Net=+3 | Growth EPS=+13.8% | Growth Revenue=+10.5%
EPS next Year (2027-12-31): EPS=2.62 | Chg7d=-0.088 | Chg30d=-0.063 | Revisions Net=+2 | Growth EPS=+11.5% | Growth Revenue=+8.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 7.9% - Earnings Yield 3.1%)
[Growth] Growth Spread = +6.3% (Analyst 11.2% - Implied 4.9%)